← Patent-cliff monitor small molecule SUNLENCA LENACAPAVIR SODIUM
Loss of exclusivity August 2041 latest FDA-listed patent expiry
Drug detail Brand name SUNLENCA Active ingredient LENACAPAVIR SODIUM Strength EQ 300MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2022 Marketing status RX
Listed patents Patent Expires Type 11944611 August 2041 use U-3507 11267799 August 2038 substance 10654827 August 2037 use U-3507 10071985 August 2037 substance, product 9951043 February 2034 substance, product
Regulatory exclusivity Code Expires NCE December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.